Mersana, Takeda deal

Mersana and Takeda expanded their 2014 deal to create antibody-drug conjugates (ADCs) comprised of antibodies from Takeda’s Millennium Pharmaceuticals Inc. subsidiary and cytotoxic payloads from Mersana to treat cancer. The expanded deal will provide Takeda with access to additional targets within Mersana’s Fleximer ADC platform and gives Mersana an option at the end of Phase I testing to co-develop and co-commercialize one of the programs in the U.S. Additionally, the companies will develop new payloads for use with ADCs. ...